Company intelligence / Profile preview
Masker MedTech
Malmö, Skåne, Swedenmaskermedtech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Masker MedTech is developing 2MA1, an inhaled, modified soluble human ACE2 protein-based antiviral candidate that in preclinical SARS-CoV-2 mouse models significantly reduced mortality, weight loss, and systemic inflammation, and improved cell viability versus remdesivir, and is being advanced toward human clinical trials.[1]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- ProteinBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Lund UniversityVINNOVA
Beyond the preview
Go deeper on Masker MedTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Masker MedTech.